CYTOMX THERAPEUTICS
CytomX Therapeutics is a biotechnology company that focuses on developing proteolytically-activated antibodies. Their mission, alone and with the help of partners, is to provide patients with more effective and less toxic therapies for severe illnesses such as cancer and inflammatory diseases.
CYTOMX THERAPEUTICS
Industry:
Biotechnology Health Care Pharmaceutical Therapeutics
Founded:
2008-01-01
Address:
South San Francisco, California, United States
Country:
United States
Website Url:
http://www.cytomx.com
Total Employee:
51+
Status:
Active
Contact:
6503510353
Total Funding:
345.42 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics WordPress Google Universal Analytics Nginx Amazon IPv6 AJAX Libraries API
Similar Organizations
AquaBounty Technologies
AquaBounty Technologies is a biotechnology company that focuses on improving productivity in commercial aquaculture.
Aura Biosciences
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.
Day One Biopharmaceuticals
Day One Biopharmaceuticals is a biotechnology company that focuses on developing new cancer therapies for patients of all ages.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2005-03-30 | Ardais Corporation | Ardais Corporation acquired by CytomX Therapeutics | N/A |
Investors List
Wellington Management
Wellington Management investment in Series D - CytomX Therapeutics
Cormorant Asset Management
Cormorant Asset Management investment in Series D - CytomX Therapeutics
Deerfield
Deerfield investment in Series D - CytomX Therapeutics
Casdin Capital
Casdin Capital investment in Series D - CytomX Therapeutics
Tekla Capital Management
Tekla Capital Management investment in Series D - CytomX Therapeutics
Perceptive Advisors
Perceptive Advisors investment in Series D - CytomX Therapeutics
Venrock
Venrock investment in Series D - CytomX Therapeutics
Redmile Group
Redmile Group investment in Series D - CytomX Therapeutics
Canaan Partners
Canaan Partners investment in Series C - CytomX Therapeutics
Third Rock Ventures
Third Rock Ventures investment in Series C - CytomX Therapeutics
Key Employee Changes
Official Site Inspections
http://www.cytomx.com Semrush global rank: 40.86 K Semrush visits lastest month: 3.13 M
- Host name: 73.38.148.146.bc.googleusercontent.com
- IP address: 146.148.38.73
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "CytomX Therapeutics"
About - CytomX
Danielle Olander-Moghadassian joined CytomX in 2014, and serves as senior vice president of talent and systems development. She is accountable for optimizing talent, bringing …See details»
Departments Management Team Archive - CytomX
Danielle Olander-Moghadassian joined CytomX in 2014, and serves as senior vice president of talent and systems development. She is accountable for optimizing talent, bringing …See details»
CytomX Therapeutics - Crunchbase Company Profile
CytomX Therapeutics is a biotechnology company that focuses on developing proteolytically-activated antibodies. Their mission, alone and with the help of …See details»
CytomX Therapeutics - LinkedIn
CytomX Therapeutics | 10,619 followers on LinkedIn. Transforming lives with safer, more effective therapies | CytomX Therapeutics, Inc. is committed to changing the treatment of cancer with …See details»
CytomX - Org Chart, Teams, Culture & Jobs - The Org
View CytomX's up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»
CytomX Therapeutics, Inc. (CTMX) - Yahoo Finance
CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California. Corporate Governance CytomX Therapeutics, Inc.’s ISS Governance QualityScore …See details»
CytomX Therapeutics Provides Strategic Update
Jul 13, 2022 We are restructuring the organization to focus on our earlier stage capabilities and programs, ... Overview of CytomX Pipeline of Conditionally Activated Product Candidates: …See details»
CytomX Therapeutics Provides Strategic Update - Yahoo Finance
Jul 13, 2022 CytomX remains committed to its current alliances with AbbVie, Amgen, Astellas, and Bristol Myers Squibb, which include the clinical-stage programs CX-2029, CX-904, and …See details»
CytomX Therapeutics Promotes Chris Ogden to Chief Financial …
Jun 17, 2024 “Chris has made broad contributions as a member of the CytomX executive team and is a proven cross-functional leader within the organization,” said Sean McCarthy, D.Phil., …See details»
Investor Relations | CytomX Therapeutics, Inc.
Nov 7, 2024 CytomX Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company dedicated to destroying cancer differently. CytomX is advancing potential first-in …See details»
Moderna and CytomX Announce Strategic Research Collaboration …
Jan 5, 2023 Collaboration will combine Moderna's mRNA technology with CytomX's Probody® Platform to generate and develop therapeutics for oncology and non-oncology conditions …See details»
Departments Board Of Directors Archive - CytomX
Dr. McCarthy joined CytomX in 2010 as the chief business officer, served as the chief executive officer (CEO) since 2011, and has been the CEO and chairman since 2019. Previously, Dr. …See details»
CytomX Therapeutics Reports Full Year 2022 Financial Results and ...
Mar 27, 2023 - CytomX to host conference call today at 5 p.m. EST / 2 p.m. PST ... “2022 was an important year of transition for CytomX as we proactively restructured our organization to …See details»
CytomX Announces Global Strategic Collaboration with Pfizer to …
Jun 6, 2013 SOUTH SAN FRANCISCO – CytomX Therapeutics, Inc., a biotechnology company developing a new generation of targeted antibody therapeutics, today announced that it has …See details»
CytomX Therapeutics, Inc. (CTMX) - Stock Analysis
5 days ago CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor …See details»
CytomX Therapeutics Announces Preliminary Results for Ongoing …
Dec 20, 2021 CytomX Therapeutics Announces Preliminary Results for Ongoing Phase 2 Expansion Study of CX-2029, a First-in-Class Antibody-Drug Conjugate Candidate Targeting …See details»
CytomX Therapeutics Announces Preliminary Results for
Dec 20, 2021 CytomX does not undertake and specifically disclaims any obligation to update any forward-looking statements, whether as a result of any new information, future events, …See details»
CytomX Therapeutics (CTMX) Earnings Date and Reports 2025
3 days ago CytomX Therapeutics released Q3 2024 earnings on November 7, 2024, reporting an EPS of $0.07, which beat the consensus estimate of -$0.16 by $0.23. Quarterly revenue …See details»
CytomX and Moderna Announce Strategic Research Collaboration …
Collaboration will combine Moderna’s mRNA technology with CytomX’s Probody ® Platform to generate and develop therapeutics for oncology and non-oncology conditions. CytomX to …See details»
CytomX Therapeutics, Inc. (CTMX) - Yahoo Finance
Find the latest CytomX Therapeutics, Inc. (CTMX) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»